Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotechnology firm, has announced a 1-for-12 reverse stock split of its common stock, set to take effect on August 5, 2025. This strategic move, approved by shareholders on July 9 and ratified by the board on July 11, aims to optimize market dynamics, broaden investor appeal, and align trading conditions with the interests of shareholders. Following the split, shares will trade on the NYSE American under the existing ticker 'CLDI', with a new CUSIP number of 320703 408.
The reverse stock split will convert every 12 pre-split shares into one post-split share, with fractional shares rounded up to the nearest whole share at the participant level. This adjustment will proportionally affect outstanding options, warrants, and equity plan shares, though it will not alter the par value or the number of authorized shares. The decision underscores Calidi Biotherapeutics' commitment to enhancing shareholder value and positioning the company for future growth in the competitive biotechnology sector.
For further details on the reverse stock split, interested parties can view the full press release here. Calidi Biotherapeutics continues to focus on developing targeted genetic medicine delivery platforms, with its proprietary technology designed to arm the immune system against cancer, highlighting the company's innovative approach to oncology treatment.
